Chronic Myeloid Leukemia

Common Name(s)

Chronic Myeloid Leukemia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Myeloid Leukemia" returned 1186 free, full-text research articles on human participants. First 3 results:

Molecular response to nilotinib in a patient with imatinib-intolerant e19a2-positive chronic myeloid leukemia.
 

Author(s): Tomohiro Kajiguchi, Shingo Okuno, Toshihito Ohno, Akihiro Abe

Journal: Intern. Med.. 2014 ;53(24):2801-4.

 

The BCR-ABL1 fusion gene is the molecular marker of chronic myeloid leukemia (CML). The e19a2 transcript is a rare variant associated with various clinical presentations and courses of CML. We herein present a case of e19a2-positive CML who was intolerant to initial treatment with ...

Last Updated: 16 Dec 2014

Go To URL
["Before and after CML": illness experiences and dimensions of chronic myeloid leukemia as a biographical disruption].
 

Author(s): Yeimi Alexandra Alzate López, Leny Alves Bonfim Trad

Journal: Cad Saude Publica. 2014 Oct;30(10):2199-208.

 

This article examines the illness experiences of patients with chronic myeloid leukemia (CML), focusing on dimensions that link the onset of the disease as a biographical disruption. This qualitative study was based on analysis of narratives by six patients 23 to 62 years of age who ...

Last Updated: 12 Nov 2014

Go To URL
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report.
 

Author(s): Giovanni Caocci, Marianna Greco, Giorgio La Nasa

Journal:

 

Although there is a considerable amount of data in the literature on safe discontinuation of first-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia, little is known about discontinuation of second-generation tyrosine kinase inhibitor therapy. ...

Last Updated: 12 Sep 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Myeloid Leukemia" returned 140 free, full-text review articles on human participants. First 3 results:

Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.
 

Author(s): Bing Li, Robert Peter Gale, Zhijian Xiao

Journal:

 

According to the 2008 World Health Organization classification, chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia are rare diseases. The remarkable progress in our understanding of the molecular genetics of myeloproliferative neoplasms ...

Last Updated: 18 Dec 2014

Go To URL
[Bone marrow microenvironment in chronic myeloid leukemia: implications for disease physiopathology and response to treatment].
 

Author(s): José Alejandro Aristizábal, Mauricio Chandia, María Consuelo Del Cañizo, Fermín Sánchez-Guijo

Journal: Rev Med Chil. 2014 May;142(5):599-605.

 

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm related to the presence of the BCR-ABL1 fusion gene, linked to t (9;22) (q34;q11). It is originated from an abnormal hematopoietic stem cell, which is characterized as its normal counterparts by long-term self-renewal ...

Last Updated: 27 Nov 2014

Go To URL
[Chronic myeloid leukemia stem cells: cross-talk with the niche].
 

Author(s): Jean-Claude Chomel, Djamel Aggoune, Nathalie Sorel, Ali G Turhan

Journal: Med Sci (Paris). 2014 Apr;30(4):452-61.

 

The physiological hematopoietic niche located in bone marrow is a pluricellular structure whose components are now well identified. Within this microenvironment, hematopoietic stem cells are in direct contact with mesenchymal stromal cells, osteoblasts and sinusoidal endothelial cells. ...

Last Updated: 7 May 2014

Go To URL
 
 
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
 

Status: Recruiting

Condition Summary: Chronic Phase Philadelphia Positive; BCR-ABL Positive; Chronic Myeloid Leukaemia

 

Last Updated: 22 Feb 2015

Go to URL
Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 23 Nov 2014

Go to URL
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 10 Dec 2014

Go to URL